BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

FDA Avandia Panel: A Twitter-Based Review

This article is more than 10 years old.

An FDA advisory panel is currently meeting to analyst a re-analysis of a clinical trial of the GlaxoSmithKline drug Avandia. For a summary of why this is important, read my piece from last night. This is a summary of what happened, culled from my tweets and those of others.

The discussions will resume this afternoon.